Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord. SE CONNECTER À UN COMPTE LECTEUR CRÉER UN COMPTE LECTEUR
GreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall Line
30 mars 2023 16h05 HE
|
GreenLight Biosciences
BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA) (“GreenLight” or the “Company”), a public benefit corporation striving to deliver on the full potential of RNA to...
GreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results
28 mars 2023 17h05 HE
|
GreenLight Biosciences
Two agriculture solutions now under regulatory review, pending EPA approval: Calantha™, a solution to protect potatoes, and a separate solution to protect honeybees from Varroa miteUpdated clinical...
GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Human Health R&D Day
09 mars 2023 06h59 HE
|
GreenLight Biosciences
-- Progressing human health pipeline conferring mRNA platform advantages for infectious disease and personalized oncology medicines; pursuing capital efficient strategy targeting unmet medical needs,...
GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Plant Health R&D Day
07 mars 2023 06h59 HE
|
GreenLight Biosciences
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s...
GreenLight Biosciences to Host R&D Day Series on Plant and Human Health Development Strategy
01 mars 2023 06h24 HE
|
GreenLight Biosciences
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s...
GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate
01 févr. 2023 07h20 HE
|
GreenLight Biosciences
The Rwanda FDA has given regulatory approval to GreenLight to start a Phase I/II clinical trial of its Covid-19 vaccine candidate in Rwanda. This phase I/II clinical trial is the first step in...
GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines
09 janv. 2023 07h20 HE
|
GreenLight Biosciences
The effort will combine GreenLight’s mRNA design and manufacturing expertise with EpiVax’s advanced Ancer® pipeline for personalized cancer vaccine designEpivax Therapeutics, Inc. will contribute a...
GreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
09 nov. 2022 17h07 HE
|
GreenLight Biosciences
Working toward clinical trial initiation for COVID vaccine candidate in 2023Shingles vaccine candidate selection planned for 2023 in partnership with Serum Institute of IndiaCalantha™, Colorado potato...
GreenLight Biosciences to Participate in Upcoming Investor Conferences in November
07 nov. 2022 11h25 HE
|
GreenLight Biosciences
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the potential of RNA to address some of the world’s toughest...
GreenLight Biosciences announces realignment to focus on near-term value drivers
12 oct. 2022 06h54 HE
|
GreenLight Biosciences
BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for...